Navigation Links
Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Date:9/18/2007

TOKYO, September 18 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that AD 337, an enantiomer of an approved, centrally acting, non-opioid, analgesic, has completed a Phase II proof of principle trial for the treatment of fibromyalgia syndrome (FMS).

The trial, a multi-centre, randomised, double-blind, placebo controlled, parallel group exploratory study, investigated the efficacy, safety and tolerability of AD 337 in the treatment of fibromyalgia in female subjects. In total, the trial enrolled 103 patients across 18 centres in the UK and Australia with the primary study endpoint being the difference in the Fibromyalgia Impact Questionnaire (FIQ) score, between active and placebo, after 4 weeks of treatment.

Results show that the study did not achieve a statistically significant outcome in its primary endpoint at 4 weeks. However statistical significance in FIQ was achieved at the 1 week time point and positive trends were seen throughout the study. In addition statistically significant measures in other efficacy assessments such as the Short Form McGill Pain Questionnaire and the Fibromyalgia Health Assessment Questionnaire (FHAQ) were seen at early time points. On balance it is concluded that AD 337 has some potential in the treatment of fibromyalgia syndrome.

AD 337 was well tolerated and there were no clinically significant changes in vital signs, biochemistry, haematology and cardiovascular parameters.

Commenting on these results Shinichi Tamura, CEO, said "This proof of principle study with an unoptimised formulation and dosing schedule and limited to four weeks in duration has demonstrated a degree of activity. Sosei will be evaluating these results to determine its approach to the possible further development of AD 337 in FMS and other potential indications."

Notes to Editors:

About Sosei

Sosei Group Corporation is a leading
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... DIEGO, July 30, 2015   Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... industries, today reported financial results for the second quarter ... of 2015, we remain on track to achieve our ... Chief Executive Officer of the Company. "Since our last ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as ... technical service business units, Whitehouse Laboratories is pleased to announce that it has ... the Container Center of Excellence and will be strictly dedicated to basic USP 51, USP ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... Ill. --- Imagine having one polymer and one small molecule ... which you can grow human stem cells, creating a sort ... therapy, could cloak the stem cells from the human bodys ... the stem cells to do their work. , Futuristic" Only ...
... FRANKLIN LAKES, N.J., March 27 BD (Becton,Dickinson ... global medical technology,company, and Direct Relief International, a ... joint volunteer,initiative to strengthen healthcare in Ghana. A ... to Ghana for three weeks and work side-by-side,with ...
... March 27 /PRNewswire/ - IntelliPharmaCeutics Ltd. (Delaware),is ... recently completed pilot,clinical trial for its new ... operating company IntelliPharmaCeutics,Corp. of Toronto ("IntelliPharmaCeutics" or ... patent applications for its novel ReXista(TM) abuse ...
Cached Biology Technology:Self-assembled materials form mini stem cell lab 2Self-assembled materials form mini stem cell lab 3Self-assembled materials form mini stem cell lab 4BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 2BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 3IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 2IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 3
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... 2015 The 10 th International Conference on ... October 22-25, 2015, in Shenzhen , ... celebrating its 10 th anniversary this year. Since its inauguration ... influential annual meetings in the ,omics, fields, and is one ... ICG-10 focuses on recent breakthroughs and advances in ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... Ten weeks of preventive supplementation with a natural form ... strokes reduced overall brain tissue damage, prevented loss of neural ... a new study shows. Researchers say the findings suggest ... vitamin E could be particularly helpful to people considered at ...
... A new study finds high folate intake is ... finding consistent with the findings of most previous epidemiologic ... has suggested that consumption of very high levels of ... risk of some cancers. Nonetheless, the potential importance of ...
... University of Georgia researcher has invented a new ... clothing, face masks, paper towelsand yes, even diapers, ... germ-free. The simple and inexpensive anti-microbial technology ... can be applied during the manufacturing process or ...
Cached Biology News:Study: Preventive use of one form of natural vitamin E may reduce stroke damage 2Study: Preventive use of one form of natural vitamin E may reduce stroke damage 3Study: Preventive use of one form of natural vitamin E may reduce stroke damage 4Folate intake may reduce colorectal cancer risk 2New UGA technology makes textiles permanently germ-free; targets health care-associated infections 2New UGA technology makes textiles permanently germ-free; targets health care-associated infections 3
... consists of two components used for alkaline ... ES cell-specific antibodies required to perform 100 ... become the subject of extensive investigation recently, ... because they raise several fundamental issues concerning ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... For use as a carrier ... precipitation. Physical form: Solution in ... 7.4, 1 mM EDTA Preparation ... Concentration: 10 ...
... Dithiothreitol DTT White solid.. PACKAGED UNDER ... thiols, so reaction is "driven" to completion. A ... waxy surfactant found in many other preparations. Blocks ... Purity: ≥97% by titration. Contaminants: Heavy ...
Biology Products: